Public Market Listing
170900KOSPI
Live quotes, historical charts, and market capitalization for Dong-A ST are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
9Total Assets
1Approved
1Phase 3 / Filed
7Phase 1–2 / Early
8Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
Evogliptin(Suganon) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
Udenafil(Zydena) | Phase 2/3 | PDE5Small molecule | Pulmonary Arterial Hypertension |
| Phase 2 | SGLT2Small molecule | Type 2 Diabetes | |
| Phase 2 | GPR119Small molecule | Type 2 DiabetesMASH / NASH | |
| Phase 1 | GLP-1/glucagon receptor (dual)Peptide | Obesity | |
| Phase 1 | — | Chronic Hepatitis B | |
| Phase 1 | DPP-4 / SGLT2 / AMPK pathway (triple)Small molecule | Type 2 Diabetes | |
| Preclinical / Unstaged | DPP-4 / SGLT2 (combination)Small molecule | Type 2 Diabetes |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | — | — | — | report ↗ |